Welcome to our dedicated page for Quest Diagnostics news (Ticker: DGX), a resource for investors and traders seeking the latest updates and insights on Quest Diagnostics stock.
Quest Diagnostics Inc. (NYSE: DGX) is a leading provider of diagnostic testing, information, and services in the United States, enabling people to make informed health decisions. The company provides diagnostic insights derived from the world’s largest database of clinical lab results, which aids in identifying and treating diseases, promoting healthy behaviors, and improving healthcare management.
Quest Diagnostics serves one in three adult Americans and half of the physicians and hospitals in the United States. Its workforce of nearly 50,000 employees is dedicated to transforming lives by providing actionable diagnostic insights. The company offers the broadest test menu available, with over 3,000 different tests, and has a strong focus on cancer diagnostics, anatomic pathology, and interpretive consultations through its medical and scientific staff of approximately 900 M.D.s and Ph.D.s.
In recent years, Quest Diagnostics has been at the forefront of innovation in diagnostic testing. The company has significantly invested in AI and digital pathology to enhance the accuracy and efficiency of cancer diagnoses. A notable collaboration with PathAI aims to accelerate the adoption of digital and AI pathology technologies, thereby improving the quality, speed, and efficiency of diagnosing cancer and other diseases. This partnership includes the acquisition of PathAI Diagnostics’ state-of-the-art digitized laboratory in Memphis, Tennessee, which will serve as Quest’s AI and digital R&D and solutions center.
Financially, Quest Diagnostics has shown robust performance, with annual revenues reaching $7.4 billion in 2014. The company continues to strengthen its market presence through strategic acquisitions and partnerships, expanding its services and enhancing its capabilities in specialized pathology services. The integration of digital and AI technologies across its operations has improved quality, efficiency, and customer satisfaction, positioning Quest Diagnostics as a leader in the diagnostic services industry.
Quest Diagnostics' extensive clinical testing network includes roughly 2,300 patient service centers, numerous doctors' offices, and hospitals nationwide. The company also provides clinical trials testing, risk assessment services, and information technology solutions through its diagnostic solutions segment.
By leveraging its comprehensive diagnostic insights, Quest Diagnostics aims to empower individuals and healthcare providers to make informed decisions that lead to better health outcomes, ultimately contributing to a healthier world.
Quest Diagnostics (NYSE: DGX) announced it will release its third quarter 2021 financial results on October 21, 2021, before the market opens. A conference call is scheduled to begin at 8:30 a.m. ET on the same day, accessible via phone and webcast. Participants are encouraged to dial in 10 minutes early. A replay will be available until November 4, 2021. The company emphasizes its role in improving health outcomes through diagnostic insights, serving one in three adult Americans and half of U.S. physicians and hospitals.
According to a Quest Diagnostics study published in JAMA Pediatrics, over half (50.5%) of American children under six tested have detectable lead levels in their blood. The study analyzed data from 1,141,441 children and found that children in high-poverty areas and older housing are at greater risk. Although elevated blood lead levels (≥5.0 µg/dL) have declined to 1.9%, the persistent lead exposure remains a significant public health concern. Experts emphasize the need to eliminate all lead sources, given that no safe level of lead exposure in children has been identified.
Quest Diagnostics (DGX) updated its financial outlook for 2021 amid stronger-than-expected COVID-19 molecular testing volumes, driven by the Delta variant's surge. The company now anticipates net revenues between $9.84 billion and $10.09 billion, reflecting a 4.3% increase from prior expectations. Adjusted diluted EPS is projected to range from $11.65 to $12.35. The company also expects to generate at least $2 billion in cash from operations and maintain capital expenditures around $400 million. Factors affecting future results include the pandemic's duration and reimbursement rates.
The Quest Diagnostics Health Trends study reveals a significant decline in new cancer diagnoses during the initial phases of the COVID-19 pandemic. Analyzing data from 799,496 patients, the study indicates that from March 2020 to March 2021, cancer diagnoses fell by 29.8% during early pandemic months and continued to decline by 19.1% by March 2021. This decline raises concerns over undiagnosed cancers and emphasizes the need for regular preventive care. Medical professionals warn that delayed diagnoses could lead to more advanced cancers, necessitating aggressive treatment and resulting in poorer outcomes.
Quest Diagnostics (NYSE: DGX) will present at the Morgan Stanley 19th Annual Global Healthcare Conference on September 9, 2021, at 9:30 a.m. ET. CEO Steve Rusckowski and EVP Jim Davis will discuss the company's growth strategy and the COVID-19 pandemic's impact. The presentation will be available for live streaming on the company's investor relations page and will remain archived for later viewing until October 9, 2021.
Quest Diagnostics (NYSE: DGX) has elected Ms. Tracey C. Doi to its Board of Directors, increasing the board's membership to 10. As CFO of Toyota Motor North America, Ms. Doi brings extensive experience in finance and strategic planning. Company leadership expressed confidence that her expertise will enhance Quest's capabilities in the healthcare sector. Alongside her role at Quest, Ms. Doi is involved with various organizations, contributing to risk management and corporate governance initiatives.
Quest Diagnostics (DGX) has declared a quarterly cash dividend of $0.62 per share, to be paid on October 20, 2021. Shareholders of record as of October 5, 2021 will receive this dividend. The company, a leader in diagnostic information services, highlights its commitment to improving health outcomes through diagnostic insights. Quest services about one in three adult Americans and supports numerous healthcare providers across the U.S., employing nearly 50,000 staff dedicated to transforming lives through health management.
Quest Diagnostics (DGX) reported strong Q2 2021 results, with net revenues soaring to $2,550 million, a 39.5% increase year-over-year. This marks the first time since 2019 that organic base testing revenues grew, propelled by new hospital lab contracts and increased healthcare engagement. Operating income rose 88.4% to $533 million, resulting in a diluted EPS of $4.96, a 264.2% increase. The company anticipates 2021 net revenues between $9.54 billion and $9.79 billion and adjusted diluted EPS of $10.65 to $11.35.
CLX Health has partnered with Quest Diagnostics (NYSE: DGX) to enhance COVID-19 testing access for individuals attending live events or traveling internationally. This collaboration allows users to schedule PCR/NAAT tests at Quest's patient service centers and over 750 retail pharmacy locations across the U.S., with results available within 48 hours. Quest is the first national provider to join the TrustAssure™ Global Testing Platform, which coordinates testing locations for major airlines and event venues. This initiative aims to facilitate safer travel experiences as pandemic restrictions ease.
FAQ
What is the current stock price of Quest Diagnostics (DGX)?
What is the market cap of Quest Diagnostics (DGX)?
What does Quest Diagnostics do?
How many people does Quest Diagnostics serve annually?
What are some recent achievements of Quest Diagnostics?
What kind of tests does Quest Diagnostics offer?
What is the company's approach to innovation?
How extensive is Quest Diagnostics' clinical testing network?
What role do partnerships play at Quest Diagnostics?
How does Quest Diagnostics contribute to healthcare management?
What are the company’s future plans?